Do specific operative approaches and insurance status impact timely access to colorectal cancer care?
- 19 August 2020
- journal article
- research article
- Published by Springer Nature in Surgical Endoscopy
- Vol. 35 (7) , 3774-3786
Abstract
Introduction The increased use of minimally invasive surgery in the management of colorectal cancer has led to a renewed focus on how certain factors, such as insurance status, impact the equitable distribution of both laparoscopic and robotic surgery. Our goal was to analyze surgical wait times between robotic, laparoscopic, and open approaches, and to determine whether insurance status impacts timely access to treatment. Methods After IRB approval, adult patients from the National Cancer Database with a diagnosis of colorectal cancer were identified (2010–2016). Patients who underwent radiation therapy, neoadjuvant chemotherapy, had wait times of 0 days from diagnosis to surgery, or had metastatic disease were excluded. Primary outcomes were days from cancer diagnosis to surgery and days from surgery to adjuvant chemotherapy. Multivariable Poisson regression analysis was performed. Results Among 324,784 patients, 5.9% underwent robotic, 47.5% laparoscopic, and 46.7% open surgery. Patients undergoing robotic surgery incurred the longest wait times from diagnosis to surgery (29.5 days [robotic] vs. 21.7 [laparoscopic] vs. 17.2 [open], p < 0.001), but the shortest wait times from surgery to adjuvant chemotherapy (48.9 days [robotic] vs. 49.9 [laparoscopic] vs. 54.8 [open], p < 0.001). On adjusted analysis, robotic surgery was associated with a 1.46 × longer wait time to surgery (IRR 1.462, 95% CI 1.458–1.467, p < 0.001), but decreased wait time to adjuvant chemotherapy (IRR 0.909, 95% CI 0.905–0.913, p < 0.001) compared to an open approach. Private insurance was associated with decreased wait times to surgery (IRR 0.966, 95% CI 0.962–0.969, p < 0.001) and adjuvant chemotherapy (IRR 0.862, 95% CI 0.858–0.865, p < 0.001) compared to Medicaid. Conclusion Though patients undergoing robotic surgery experienced delays from diagnosis to surgery, they tended to initiate adjuvant chemotherapy sooner compared to those undergoing open or laparoscopic approaches. Private insurance was independently associated not only with access to robotic surgery, but also shorter wait times during all stages of treatment. Graphic AbstractKeywords
This publication has 25 references indexed in Scilit:
- Racial and Socioeconomic Disparities in the Surgical Management and Outcomes of Patients with Colorectal CarcinomaWorld Journal of Surgery, 2019
- Trends and Outcomes of Surgical Treatment for Colorectal Cancer between 2004 and 2012- an Analysis using National Inpatient DatabaseScientific Reports, 2017
- Insurance Status, Not Race, is Associated With Use of Minimally Invasive Surgical Approach for Rectal CancerAnnals of Surgery, 2017
- A comparison of trends in operative approach and postoperative outcomes for colorectal cancer surgeryJournal of Surgical Research, 2017
- Robotic, laparoscopic, and open colectomy: a case‐matched comparison from the ACS‐NSQIPThe International Journal of Medical Robotics and Computer Assisted Surgery, 2016
- Comparison of robotic and laparoscopic colorectal resections with respect to 30-day perioperative morbidityCanadian Journal Of Surgery, 2016
- A comparison of laparoscopic and robotic colorectal surgery outcomes using the American College of Surgeons National Surgical Quality Improvement Program (ACS NSQIP) databaseSurgical Endoscopy, 2015
- National disparities in minimally invasive surgery for rectal cancerSurgical Endoscopy, 2015
- Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trialThe Lancet Oncology, 2014
- Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trialThe Lancet Oncology, 2013